PF-4136309

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NamePF-4136309
Drug Alias NamePF-4136309INCB-8761PF-04136309
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsOsteoarthritis, KneePancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSingapore +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington University School Of MedicinePfizer IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsOsteoarthritis, KneePancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4] 

Other Information

ATC CodeN/A
Related LinksN/A